Selective Serotonin Reuptake Inhibitors (SSRIs) have been linked to persistent sexual dysfunction that may remain even after patients discontinue the medication. The condition, known as Post-SSRI Sexual Dysfunction (PSSD), involves genital numbness, loss of libido, and an inability to experience sexual or emotional pleasure.
The Food and Drug Administration has been aware of these adverse effects for years but has not issued a black box warning, unlike regulatory counterparts in Europe. Critics argue the agency's inaction reflects a broader pattern of delayed responses to antidepressant risks.
Some medical discussions have framed SSRI-induced sexual dysfunction as a diagnosable "condition" rather than a drug side effect. Advocates stress that the symptom is an adverse reaction and should not be treated with additional psychiatric medication.
Reports indicate that a pharmaceutical manufacturer informed the FDA of persistent sexual dysfunction cases from clinical trials in 2011. Despite this, patients were not systematically warned about the risk prior to being prescribed the drugs.
In a 2018 public comment submitted to the agency, a young woman described losing all sexual sensation and emotional responsiveness after taking an SSRI. She died by suicide one year later at age 21.
A board member of a support network for PSSD sufferers states that the FDA's failure to update drug safety labeling has contributed to preventable harm, including suicides. The network urges the agency to mandate a boxed warning for PSSD.
The FDA approved the first SSRI within four years of review, yet has moved slowly on safety warnings for known adverse effects. The agency's passive approach to monitoring and disclosing drug reactions continues to draw scrutiny.
Concerns persist about underreporting of sexual and emotional blunting through the FDA's adverse event system. Without stronger labeling requirements, advocates warn that more patients remain unaware of potentially permanent risks.
